Last year's FDA approvals reflect lingering drug R&D drought

01/9/2008 | Star-Ledger (Newark, N.J.), The

Preliminary figures show that the FDA approved only 16 "new molecular entities" and vaccines and two biotech drugs in 2007, highlighting the continued scarcity of promising treatments in development. Drugmakers and analysts attribute the trend to the agency's tighter regulation since Merck & Co.'s Vioxx was withdrawn from the market, but the FDA insists that its oversight was not affected by the Vioxx controversy.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Brief:

SmartBrief Job Listings for Health Care